Ernexa Therapeutics ERNA-101 Shows Durable Tumor Regression With PD-1 Blockade In Preclinical Ovarian Cancer Models; IND Submission Planned Q3 2026; First-In-Human Trial Expected Q4 2026

Ernexa Therapeutics (NASDAQ: ERNA) has reported promising preclinical results for its lead product candidate, ERNA-101, which shows durable tumor regression in combination with PD-1 blockade for the treatment of platinum-resistant ovarian cancer. The company plans to submit an Investigational New Drug (IND) application in Q3 2026, with the first-in-human trial expected to begin in Q4 2026. The combination therapy demonstrated high rates of complete tumor regressions and significantly prolonged survival in preclinical models, positioning ERNA-101 as a potential foundational immunotherapy platform.